Compounds > 1,25-dihydroxy-19-norvitamin d3
Page last updated: 2024-11-11

1,25-dihydroxy-19-norvitamin d3

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1,25-dihydroxy-19-norvitamin D3: RN refers to (1alpha,3beta,7E)-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9547326
CHEMBL ID119386
SCHEMBL ID12047912
MeSH IDM0222385

Synonyms (19)

Synonym
1alpha,25-dihydroxy-19-norvitamin d3 / 1alpha,25-dihydroxy-19-norcholecalciferol
(7e)-(1r,3r)-19-nor-9,10-seco-5,7-cholestadiene-1,3,25-triol
LMST03020074 ,
CHEMBL119386
1,25-dihydroxy-19-norvitamin d3
130447-37-9
20-epi-19-nor-1,25-(oh)2 d3
1alpha,25-(oh)2-19-nor-vitamin d3
1,3-cis-25-dihydroxy-19-norvitamin d3
19-nor-22(e)
19-nor-9,10-secocholesta-5,7-diene-1,3,25-triol, (1alpha,3beta,7e)-
k5zm856psa ,
unii-k5zm856psa
SCHEMBL12047912
19-nor-vitamin d
1,3-cyclohexanediol, 5-((2e)-2-((1r,3as,7ar)-octahydro-1-((1r)-5-hydroxy-1,5-dimethylhexyl)-7a-methyl-4h-inden-4-ylidene)ethylidene)-, (1r,3s)-
19-nor-1.alpha.,25-dihydroxyvitamin d3
PKFBWEUIKKCWEW-WEZTXPJVSA-N
(1r,3r)-5-[(2e)-2-[(1r,3as,7ar)-1-[(2r)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Young chicks were used to evaluate the efficacy of 2 new vitamin D3 analogs relative to 1 alpha-hydroxycholecalciferol (1 alpha-OH D3) for their ability to improve the bioavailability of phytate-bound phosphorus (P) when added to P-deficient maize-soyabean meal diets that were superadequate in cholecalciferol."( Activity of various hydroxylated vitamin D3 analogs for improving phosphorus utilisation in chicks receiving diets adequate in vitamin D3.
Baker, DH; Biehl, RR; Deluca, HF, 1998)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID81829In vitro induction of cell differentiation in HL-60 cells relative to 1,25(OH)2D3 (100)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20.
AID216845Binding affinity for human vitamin D binding protein (hDBP) relative to 1,25(OH)2D3 (100)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20.
AID217011Binding affinity for porcine intestinal Vitamin D3 receptor (VDR) relative to 1,25(OH)2D3 (100)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20.
AID110582Hypercalcemic effect by daily sc injection of compound was measured as serum calcium concentration in vitamin D-replete normal NMRI mice relative to 1,25(OH)2D3 (100)1999Journal of medicinal chemistry, Sep-09, Volume: 42, Issue:18
Synthesis, biological activity, and conformational analysis of four seco-D-15,19-bisnor-1alpha,25-dihydroxyvitamin D analogues, diastereomeric at C17 and C20.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (22.22)18.2507
2000's15 (55.56)29.6817
2010's6 (22.22)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.02

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.02 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.02)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
phytic acid
Phytic Acid: Complexing agent for removal of traces of heavy metal ions. It acts also as a hypocalcemic agent.. myo-inositol hexakisphosphate : A myo-inositol hexakisphosphate in which each hydroxy group of myo-inositol is monophosphorylated.		1.9910inositol phosphate
1-anilino-8-naphthalenesulfonate
1-anilino-8-naphthalenesulfonate: RN given refers to parent cpd. 8-anilinonaphthalene-1-sulfonic acid : A naphthalenesulfonic acid that is naphthalene-1-sulfonic acid substituted by a phenylamino group at position 8.		210aminonaphthalene;
naphthalenesulfonic acid		fluorescent probe
thymidine
[no description available]		210pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
vinyl fluoride
[no description available]		2.0310gas molecular entity;
monohaloethene
quinic acid
(-)-quinic acid : The (-)-enantiomer of quinic acid.		2.1310
tiletamine hydrochloride
Cyclohexanones: Cyclohexane ring substituted by one or more ketones in any position.. cyclohexanones : Any alicyclic ketone based on a cyclohexane skeleton and its substituted derivatives thereof.		210
calcitriol
dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes		5.76270D3 vitamins;
hydroxycalciol;
triol		antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical
cholecalciferol
Cholecalciferol: Derivative of 7-dehydroxycholesterol formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. It differs from ERGOCALCIFEROL in having a single bond between C22 and C23 and lacking a methyl group at C24.. calciol : A hydroxy seco-steroid that is (5Z,7E)-9,10-secocholesta-5,7,10(19)-triene in which the pro-S hydrogen at position 3 has been replaced by a hydroxy group. It is the inactive form of vitamin D3, being hydroxylated in the liver to calcidiol (25-hydroxyvitamin D3), which is then further hydroxylated in the kidney to give calcitriol (1,25-dihydroxyvitamin D3), the active hormone.		1.9810D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone		geroprotector;
human metabolite
maxacalcitol
maxacalcitol: structure given in first source		210organic molecular entity
acid phosphatase
Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.		2.0810
calcipotriene
calcipotriene: a topical dermatologic for the treatment of moderate plaque psoriasis; structure in first source. calcipotriol hydrate : A hydrate that is the monohydrate form of calcipotriol. It is used in combination with betamethasone dipropionate, a corticosteroid, for the topical treatment of plaque psoriasis in adult patients.		1.9910hydrateantipsoriatic
ConditionIndicatedRelationship StrengthStudiesTrials
Bone Demineralization, Pathologic
Decrease, loss, or removal of the mineral constituents of bones. Temporary loss of bone mineral content is especially associated with space flight, weightlessness, and extended immobilization. OSTEOPOROSIS is permanent, includes reduction of total bone mass, and is associated with increased rate of fractures. CALCIFICATION, PHYSIOLOGIC is the process of bone remineralizing. (From Dorland, 27th ed; Stedman, 25th ed; Nicogossian, Space Physiology and Medicine, 2d ed, pp327-33)		02.0810
Chronic Kidney Failure
[description not available]		02.0810
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.		02.0810
Cancer of Liver
[description not available]		02.9910
Cancer of Prostate
[description not available]		02.9910
Liver Neoplasms
Tumors or cancer of the LIVER.		02.9910
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.9910
Osteogenic Sarcoma
[description not available]		01.9810
Osteosarcoma
A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed)		01.9810
Carcinoma, Oat Cell
[description not available]		01.9910
Milk-Alkali Syndrome
[description not available]		01.9910
Cancer of Lung
[description not available]		01.9910
Hypercalcemia
Abnormally high level of calcium in the blood.		01.9910
Lung Neoplasms
Tumors or cancer of the LUNG.		01.9910
Carcinoma, Small Cell
An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)		01.9910
Bone Loss, Osteoclastic
[description not available]		0210